The availability of oral direct-acting antivirals has altered the hepatitis C virus (HCV) treatment paradigm for both preliver transplant (LT) and post-LT patients. There is a perceived trade-off between pre-LT versus post-LT treatment of HCV-treatment may improve liver function but potentially decrease the likelihood of a necessary LT. Our objective was to identify LT-eligible patients with decompensated cirrhosis who would benefit (and not benefit) from pre-LT treatment based on their Model for End-Stage Liver Disease (MELD) scores. We simulated a virtual trial comparing long-term outcomes of pre-LT versus post-LT HCV treatment with oral direct-acting antivirals for patients with MELD scores between 10 and 40. We developed a Markov-based microsimulation model, which simulated the life course of patients on the transplant waiting list and after LT. Simulation of LT integrated data from recent trials of oral direct-acting antivirals (SOLAR 1 and 2), the United Network for Organ Sharing (UNOS), and other studies. The outcomes of the model included life expectancy, 1-year and 5-year patient survival, and mortality. Model-predicted patient survival was validated with UNOS data. We found that, at the national level, treating HCV before LT increased life expectancy if MELD was £ 27 but could decrease life expectancy at higher MELD scores. Depending on the UNOS region, the threshold MELD score to treat HCV pre-LT varied between 23 and 27 and was lower for UNOS regions 3, 10, and 11 and higher for regions 1, 2, 4, 5, 8, and 9. Sensitivity analysis showed that the thresholds were stable. Conclusion: Our findings suggest that the optimal MELD threshold below which decompensated cirrhosis patients should receive HCV treatment while awaiting LT is between 23 and 27, depending on the UNOS region. (HEPATOLOGY 2017;65:777-788) 
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H epatitis C virus (HCV) is the leading indication for liver transplantation (LT) in the United States.
(1) Despite recent advances in HCV treatments, the burden on the transplant waiting list is projected to remain substantial even in the era of oral direct-acting antivirals (DAAs). (2) In patients who develop decompensated cirrhosis, the risk of death in the following year is approximately 15%-20%, and LT generally remains the only life-saving option. (3) However, reinfection with HCV after transplantation occurs virtually universally; allograft hepatitis C can be rapidly progressive, and retransplantation is the only therapeutic option for long-term survival in patients who advance to end-stage liver disease after LT. (4, 5) Until recently, the management of HCV in patients with decompensated cirrhosis and those who underwent LT was challenging because of low efficacy and tolerance of interferon-based therapies. (5) However, the availability of oral DAAs has altered the treatment paradigm for both pre-LT and post-LT patients. Treatment of HCV in these difficult-to-treat patients is feasible, with high success rates, even in those who previously failed interferon-based therapy. (6) The successful use of DAAs has been associated with improvements in Model for End-Stage Liver Disease (MELD) score and dramatic reductions in the rate of HCV recurrence after LT and, by extension, the need for retransplantation. (5, 7) Similarly, successful post-LT antiviral treatment is associated with fibrosis stabilization or regression and improved graft survival, which was difficult to achieve prior to the availability of DAAs. (8) The decision to treat HCV pre-LT or post-LT has been widely debated. (9, 10) There is a trade-off between pre-LT and post-LT treatment of HCV, and it is not clear which patients will benefit from pre-LT treatment and which ones will be better served by waiting until posttransplantation. This is because pre-LT treatment of HCV can improve patients' MELD score and improve survival on the waiting list but could delay their LT by moving them further down the waiting list. By improving MELD score by a few points, some patients could also fall below the range for LT while not significantly improving their health. This situation has been termed "MELD limbo" or "MELD purgatory." (9) In addition, by eradicating HCV pre-LT, these patients will no longer be eligible to receive an HCV-positive donor organ, which could further reduce their likelihood of receiving LT. Therefore, some patients may be better off treating HCV after the LT. On the other hand, not providing HCV treatment pre-LT and waiting until the LT could result in worsening of the underlying liver condition (by increasing the patient's MELD score) and increase the likelihood of mortality on the waiting list. Ideally, a randomized controlled trial comparing HCV treatment pre-LT with post-LT for patients for each MELD score could inform the optimal timing of HCV treatment. However, such a trial will be prohibitively large and time-consuming. In such situations, mathematical modeling can inform optimal strategies (11, 12) and has been used to inform clinical decisions in organ transplantation. (13) (14) (15) The objective of our study was to identify LT-eligible patients with decompensated cirrhosis who will benefit from HCV treatment pre-LT based on their MELD scores (and those who will not), using a mathematical model. We sought to determine a threshold MELD score below which pre-LT HCV treatment would improve patients' expected life and vice versa, and to determine the factors that influence this threshold.
Materials and Methods

MODEL OVERVIEW
We simulated a virtual trial comparing long-term outcomes of pre-LT versus post-LT HCV treatment with oral DAAs for genotype 1 and 4 patients having MELD scores between 10 and 40. For that purpose,
ARTICLE INFORMATION:
we developed a Markov-based microsimulation model (individual-level state transition model) that simulated the life course of patients on the transplant waiting list to evaluate the comparative effectiveness of HCV treatment pre-LT versus post-LT (Fig. 1) . Our simulation of LT model integrates data from multiple clinical studies including recent trials of oral DAAs, data from the United Network for Organ Sharing (UNOS), and other published studies. Simulation of LT follows patients on the transplant waiting list, keeps track of their MELD scores, and simulates the natural history of their disease after the transplantation. The outcomes of the model include expected life years, qualityadjusted life years, 1-year and 5-year patient survival, and death from background and liver-related causes. The model was developed in the Java programming language from the patient perspective with a lifetime time horizon. We used a weekly cycle length to advance time in the model. We ran our model 1 million times to account for first-order uncertainty.
BASELINE POPULATION
The baseline population consisted of patients with decompensated cirrhosis having MELD scores in the range 10-40. The mean age of patients was 50, and we assumed that they had HCV genotype 1 or 4.
INTERVENTIONS
For each patient, we simulated two scenarios to compare the long-term outcomes: 1) HCV treatment on the waiting list and 2) HCV treatment after the LT. Patients were treated with sofosbuvir and ledipasvir plus ribavirin for up to 12 weeks before transplantation. The sustained virologic response (SVR) rates of sofosbuvir plus ledipasvir when treated pre-LT were derived from the SOLAR-1 and SOLAR-2 studies (16) (17) (18) (Table 1) . Though these studies used sofosbuvir-based therapy, our analysis is not limited to any particular regimen and applies to other regimens that are currently used or will be approved in the near future. We conducted a sensitivity analysis on a wide range of SVR rates.
If patients received less than 6 weeks of antiviral therapy before the transplant, we assumed that the treatment was incomplete and did not result in SVR. (16) (17) (18) However, if patients received at least 6 weeks of antiviral therapy before the transplant, we assumed that the treatment was complete and that the patients would achieve SVR as reported by clinical studies. Patients who failed to achieve SVR after the pre-LT antiviral treatment were retreated 3 months after the transplant. We selected the 3-month window as a time point that was sufficiently distanced from the perturbations of the immediate post-LT period but sufficiently early before progressive allograft disease could develop. The SVR rates of post-LT treatment were 95%, as reported by the combined analysis of the SOLAR-1 and SOLAR-2 studies. (16) (17) (18) As in the pre-LT case, our analysis is also applicable to other DAA combinations that have been used for post-LT antiviral treatment. (19) For the comparator arm, "HCV treatment after the LT," we simulated a scenario where patients on the waiting list did not receive HCV treatment until after LT. While on the waiting list, patients' MELD scores could change naturally. Based on their MELD scores, they could either undergo LT or die due to liverrelated mortality or all-cause mortality. Three months after the transplant, all patients were offered antiviral treatment. We used SVR rates of 95% and conducted a sensitivity analysis (Table 1) .
DISEASE PROGRESSION
In the pre-LT setting, we simulated changes in MELD scores. We used a previously published study based on UNOS data to estimate weekly increase or decrease in MELD score, i.e., the natural course of the disease. (13, 20) Specifically, data from 1,997 HCV-infected patients on the LT waiting list from UNOS were used to create cubic splines of bilirubin, creatinine, albumin level, and prothrombin time for each patient. The splines were then sampled at regular intervals to obtain a complete longitudinal history of each patient over time. Data were aggregated in groups of paired consecutive MELD scores starting with 10-11, 12-13, etc. We also estimated mortality on the waiting list based on the MELD score as from the same data source (Supporting Table S1 ). We assumed that during the treatment MELD score would follow the natural history, i.e., increase, decrease, or remain constant. Four weeks after the end of treatment, we adjusted the MELD score based on the treatment response as reported by the combined analysis of SOLAR 1 and 2 trials. (16) (17) (18) Supporting Fig. S1 shows the probability of increase, decrease, and no change in MELD score 4 weeks after the end of treatment. If the patient achieved SVR, the MELD score was probabilistically updated according to the data reported in Supporting Fig. S1 ; otherwise, the MELD score continued to follow the natural course of the disease.
After the LT, patients' natural history was determined by the status of their HCV infection-SVR or viremic. Recurrent HCV infection is universal among patients who are viremic at LT, the majority of whom will have histological evidence of recurrent hepatitis within the first year after LT. (21) Therefore, in our model we treated viremic HCV patients 3 months after LT. Patients could die because of liver-related mortality, and the graft could fail due to recurrent allograft HCV or other reasons. (22) After graft failure, patients could undergo retransplantation.
LIVER TRANSPLANTATION
We used a published study to estimate the weekly probability of getting LT based on the patient's MELD score. (23) Supporting Table S2 provides the 3-month probability of LT that was converted to weekly probability in our model. We accounted for reduction in the likelihood of LT if the patient's HCV was treated on the waiting list because this individual would no longer be eligible to receive an HCVpositive liver. Specifically, we reduced the probability of undergoing LT by 8% because among all LTs in HCV-positive recipients, 8% had an HCV-positive donor graft. (24) In the sensitivity analysis, we varied this percentage between 5% and 15%. Patients who needed retransplantation went back on the LT waiting list. Because we did not know their MELD score, we assigned the average probabilities of LT and liverrelated mortality to these patients, which were estimated from UNOS data (Supporting Information).
HEALTH-RELATED QUALITY OF LIFE
For each individual in our model, we assigned health-related quality-of-life weights, with 0 denoting death and 1 denoting perfect health, and adjusted them for age and sex. We derived EuroQol-5D instrument (Rotterdam, The Netherlands) values from a previous study and adjusted them to the US population norm (Supporting Table S3 ). (25) (26) (27) 
OUTCOMES
We projected life years and quality-adjusted life years for each MELD score (aggregated in groups of two) for pre-LT and post-LT scenarios. We also projected 1-year and 5-year survival after LT. We further projected these outcomes for each of the 11 UNOS regions. For that purpose, we adjusted the probability of undergoing LT and mortality on the waiting list for each region using region-specific transplantation and death rates (see Supporting Information and Table S4 for details).
SENSITIVITY ANALYSIS
We performed one-way sensitivity analysis to estimate the effects of all transition probabilities and quality-of-life weights on change in the decision to treat pre-LT or post-LT. We further conducted probabilistic sensitivity analysis by jointly varying all model parameters over 3,000 simulations, then calculating 95% confidence intervals for each model outcome based on the results. We used the recommended statistical distributions to define uncertainty around each input parameter as defined in Supporting Table S5 .
Because of a declining pool of HCV-positive LT recipients on the transplant waiting list, their likelihood of receiving an LT will progressively increase. Therefore, we conducted a sensitivity analysis by increasing the likelihood (from the base case) of receiving an LT by 8%, which is consistent with the decrease in likelihood of LT by 8% in HCV-negative patients. We further sought to determine the specific magnitude of the increased likelihood of receiving a transplant that would trigger a change in the threshold for treatment of HCV pre-LT.
Results
We first validated the predicted 1-year and 5-year transplant survival rates with those from UNOS data. Because UNOS data provide survival rates in the pre-DAA era, we simulated the scenario using pre-DAA therapies (Supporting Information) and found that the model's predicted survival rates aligned closely with the rates estimated by the Organ Procurement Transplant Network data (Supporting Fig. S2 ).
MELD SCORE THRESHOLD FOR HCV TREATMENT
We estimated the expected life years as a function of timing of HCV treatment: pre-LT versus post-LT. Figure 2 shows that life expectancy was dependent on patients' MELD score as well as the timing of HCV treatment. Life expectancy decreased with increases in MELD score on the LT waiting list. For patients with lower MELD scores, life expectancy was higher when HCV was treated pre-LT and lower if treated post-LT. The trend was reversed for higher MELD scores. We also plotted the difference in life expectancy if HCV was treated pre-LT versus post-LT (Fig. 3) . The 95% confidence intervals remained positive for MELD 27, indicating that patients with MELD 27 would benefit if HCV was treated pre-LT. For patients with MELD >27, providing HCV treatment pre-LT did not offer benefit and, in fact, was associated with decreased life expectancy in some cases. Similar trends were also observed in quality-adjusted life years under pre-LT versus post-LT scenarios (Supporting Figs. S3 and S4).
ANALYSIS BY UNOS REGIONS
We further analyzed the results for each UNOS region to account for differences in waiting time for LT (Fig. 4) . We found that the threshold MELD score below which treating HCV pre-LT increased life expectancy compared to waiting until after the LT varied by region. The threshold was higher in regions with longer time on the LT waiting list and lower in regions with shorter time on the LT waiting list. For instance, region 3, which has the shortest waiting time on the LT waiting list, had a MELD threshold of 23, and region 9, which has the longest waiting time, had a threshold of 27. We also observed that the benefits (i.e., difference in life expectancy) of antiviral treatment pre-LT were higher in regions having longer times on the LT waiting list (Fig. 5) . For instance, a patient in region 3 having a MELD score of 20-21 on the waiting list would gain 0.42 life years with pre-LT (versus post-LT) HCV treatment, whereas the corresponding patient in region 9 would gain 2.62 life years.
SENSITIVITY ANALYSIS
We conducted a one-way sensitivity analysis to identify parameters that exerted the strongest influence on the MELD score threshold, i.e., which parameters could change the decision to treat HCV pre-LT versus post-LT. For this purpose, we simulated change in life expectancy in patients with by treating pre-LT, irrespective of the value of the input variable (higher or lower); i.e., the optimal decision was to treat HCV pre-LT if MELD was 27. Similarly, for patients with a MELD score of 30-31, life expectancy always decreased by treating pre-LT, irrespective of the value of the input variable. This implies that the optimal decision was to treat post-LT if MELD was 30. For patients with a MELD score of 28-29, the difference in life expectancy with pre-LT versus post-LT treatment remained positive but close to 0, irrespective of the value of input variables.
When we increased the likelihood of getting an LT in HCV-positive patients on the transplant waiting list, the threshold MELD score to treat HCV pre-LT fell below 26 when the rate of LT in HCV-positive patients increases by 10% (Supporting Fig. S5) . Similarly, we found that the threshold to treat HCV pre-LT changed to a MELD score of <24 when the rate of LT in HCV-positive patients increased by 40% (Supporting Fig. S6 ).
Discussion
The availability of DAAs has changed the HCV treatment paradigm in LT candidates as well as recipients. In this study, we evaluated the trade-off between pre-LT and post-LT treatment of HCV with DAAs-treatment can improve liver function but potentially decrease the likelihood of transplant. Our findings suggest that the optimal threshold to treat HCV in decompensated cirrhosis patients on the transplant waiting list is a MELD score of 23-27, depending on the UNOS region. Patients below these MELD thresholds could benefit from HCV treatment before the transplant; however, treating HCV above these thresholds may be associated with decreased life expectancy. Our results may help inform clinicians about the timing of HCV treatment in LT candidates.
In this study, we determined the optimal timing of HCV treatment in LT-eligible patients that has been raised in recent studies. (9, 10) Our results align with the opinion expressed in these studies that in some patients clearing HCV infection before transplantation may have paradoxical consequences, in that their decreased odds of undergoing transplantation will not be offset by their improved liver function while on the waiting list. Our study evaluates (and quantifies) such trade-offs from the clinical and patient perspectives. Other modeling-based studies have addressed this topic. However, those studies evaluated the cost-effectiveness of HCV treatment pre-LT versus post-LT, (28, 29) which should not preempt the comparative effectiveness analysis from the patient perspective, the focus of the current study. The question of cost-effectiveness, while important, may not be used to inform the clinical decision of pre-LT versus post-LT treatment of HCV. Instead, such an analysis could inform the choice of drugs among multiple options that could be cost-effective from the payer's perspective. Another study evaluated the timing of HCV treatment with pegylated interferon and ribavirin, whose results may not be applicable in the era of DAAs. (30) Our study has numerous strengths. First, we conducted a comprehensive analysis of the trade-offs of HCV treatment pre-LT versus post-LT by simulating a virtual trial that compared the long-term outcomes in patients under the two scenarios. Conducting such a clinical trial in real life could be prohibitively expensive and time-consuming. Second, our simulation of LT model incorporated data from recently published clinical trials, the Organ Procurement Transplant Network, and other sources and has been validated with UNOSreported patient outcomes. Therefore, our analysis provides strong evidence to inform clinical decision making. Third, our study highlights that the timing of HCV treatment is dependent on a patient's MELD score as well the UNOS region.
While the guidance offered by this model is useful, it is not meant to be used as an algorithm for HCV treatment for every patient. There are several factors (such as refractory complications of portal hypertension) that determine the patient's urgency for LT that are not reflected in MELD alone. Therefore, our results may not apply to these situations. In addition, our analysis did not include decompensated cirrhosis patients having HCC, a considerable portion of the patients on the waiting list. Such patients will have a different natural history of the disease and are outside the scope of the current model.
Our study has a number of limitations. First, longterm data on transplant recipients who achieved SVR are extremely limited, especially when considering different MELD groups. Therefore, we assumed that the patient and graft survival would be similar to those of non-HCV transplant recipients. In addition, longterm data on MELD score changes after HCV treatment were based on the two SOLAR studies only. We will need to reanalyze our results as more data become available in the future.
(31) Second, we did not explicitly model Child-Turcotte-Pugh class in our analysis. Third, we assumed that patients would be treated only once after the transplant. Although the SVR rates are very high, around 5% of patients will fail post-LT treatment with existing DAAs; and we assumed that these patients will not be eligible for retreatment. However, we expect that the majority of these patients could be successfully treated in the near future. Fourth, we did not model patient dropout from the waiting list resulting from MELD improvement because limited data are available to inform such a decision. In our opinion, this exclusion will not affect our primary analysis of optimal MELD threshold for HCV treatment pre-LT versus post-LT. Fifth, our model did not adjust for survival based on MELD score at transplant, and adjusting for survival could have resulted in a higher MELD threshold to provide post-LT HCV treatment. Finally, our model did not account for potential reduction in the LT waiting list because of delisting of HCV patients after successful antiviral therapy and decreasing need for LT in HCV patients because of the availability of DAAs. (32) Their inclusion could have resulted in a lower MELD score threshold to provide post-LT HCV treatment.
Sensitivity analysis suggested that our model results remain robust as changes to model input variables did not appreciably change the model findings. None of the variables had a significant influence on the MELD threshold. We also accounted for overall uncertainty by conducting probabilistic sensitivity analysis and generated 95% confidence intervals.
We observed differences in HCV treatment recommendations by UNOS regions. Because LT wait times vary across regions, patient-level decisions to treat HCV pre-LT versus post-LT should be dependent on UNOS region. In future, rezoning of UNOS regions could reduce disparities in time spent on the waiting list; our analysis will therefore need to be evaluated in this context. The reduction of these disparities can be expected to narrow the threshold range, which could simplify decision making.
In conclusion, our study evaluated the trade-off of providing HCV treatment before and after LT in decompensated patients. The optimal MELD score threshold indicating whether to treat HCV pre-LT versus post-LT in these patients is between 23 and 27, depending on the UNOS region. Patients below the threshold will benefit from initiating treatment before LT, and those above the threshold will benefit from waiting until after LT for treatment. These data should be useful in informing decision making for patients with HCV infection who are awaiting LT.
